Dr. Martin is the President, Chief Executive Officer, and a member of the Board of Directors.

Michael brings tremendous experience to Plexium as a scientific executive, global R&D leader, venture investor and corporate board member. Michael joined Plexium following his roles at Takeda Pharmaceuticals, serving most recently as the Global Head of the Center for External Innovation where he was a key member of Takeda’s Leadership Team. While in this role, he was responsible for external research & development activities including Business Development, Search & Evaluation, Strategy & Operations, Academic Alliances, and Takeda Ventures, Inc. Prior to his most recent role at Takeda, Michael was President of Takeda Ventures, Inc., Takeda’s corporate venture capital company. He also previously held executive and scientific roles with Intellikine Inc. (acquired by Takeda), TargeGen, Inc. (acquired by Sanofi-Aventis), Arena Pharmaceuticals, Inc. (acquired by Pfizer) and Monsanto Corporation (acquired by Bayer).

Michael holds a Ph.D. in Medicinal Chemistry from University of Illinois, a M.S. in Analytical Chemistry and B.S. degrees in Chemistry and Mathematics. He has extensive experience as a corporate board member, for both private and publicly traded companies, and has acted as an advisor to several notable biotech investment funds in the United States, Europe, and Japan.